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Bullous pemphigoid (BP) is the most frequent autoimmune bullous skin disease, characterised by auto-
antibodies against the hemidesmosome complex. Recently, regulatory T cells (Tregs) have been implicated 
in the development of several autoimmune diseases; few data are available in BP, failing to demonstrate a 
role of this subset in disease pathogenesis. The aim of this study was to investigate the expression and 
phenotypes of different Tregs (CD4+ CD25brightFOXP3+ and CD8+ CD28- cells) in BP to clarify whether the 
depletion of this subset constitutes one mechanism of tolerance loss. The CD4+ CD25bright-FOXP3 and 
CD8+ CD28- circulating subsets were determined by flow-cytometry in 26 untreated BP patients and 
compared with a group of age- and sex-matched healthy controls (HC, n = 30). Absolute and percentage 
values of the CD4+ CD25brightFOXP3+ cells were significantly reduced in BP compared with HC (median 
CD25bright- FOXP3+ expression within CD4+ cells: 1.8 vs. 3.5%, p = 0.002); conversely, BP patients were 
characterised by a significant expansion of the CD25brightFOXP3- ‘‘activated’’ T-cell subset. CCR4 and 
CD62L were expressed on the majority of CD4+ CD25brightFOXP3+ cells (75.2 and 82.3%, respectively). No 
differences in the CD8+ CD28- subset were found between BP and HC. This is the first report showing a 
significant reduction of circulating CD4+ CD25brightFOXP3+ Treg frequency in BP patients. 
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Introduction 
Bullous pemphigoid (BP), the most common autoimmune blistering disease, is characterised by presence of 
auto-antibodies directed against components of the hemidesmosome adhesion complex, the BP230 and 
collagen XVII/BP180 proteins. The pathogenesis of disease involves also development of BP180-specific 
auto-reactive T cells, accumulation of other inflammatory cells, complement activation, mast-cell 
degranulation and protease release [6, 8, 11, 38].  
Numerous immune-mediated diseases have been shown to present a reduction and/or function 
impairment of regulatory T cells (Tregs) [21, 28], a subset of effector cells which play an important role in 
tolerance control by silencing self-reactive T cells. In previous studies, we found a significant Treg down-
modulation in immune-mediated skin diseases (psoriasis, scleroderma, dermatomyositis, lupus and Graft-
versus-Host-Disease (GvHD)[1–3, 25, 26].  
Distinct Treg subsets have been described [10, 19]. The bright CD25 expression identifies both naturally 
occurring Tregs (nTregs), characterized by the intracellular expression of transcription factor forkhead-box-
P3 (FOXP3) and ‘‘antigen induced’’ Tregs, whose suppressive functions are mediated by IL-10 and TGF-b 
release. CD8+ Suppressor lymphocytes are CD28negative, do not determine apoptosis and induce immune 
suppression through an antigen- or non-antigen-specific mechanism [5, 9, 13, 14]. 
To date few studies focused on Tregs in autoimmunebullous skin diseases. A significant depletion of Tregs 
was demonstrated in pemphigus vulgaris (PV) [31, 35]. Experimental studies confirmed that FoxP3 
inhibition abrogated the suppressor activity on desmoglein3-specific cell clones [36, 37] and that anti-
desmoglein-3 auto-antibodies were suppressed by the adoptive transfer of Tregs[39]. As for BP, only two 
papers were published, reporting conflicting results [27, 4]. One study [27] failed to demonstrate significant 
differences in Treg number in both skin and blood of 14 BP patients with respect to healthy donors, Tregs 
from BP patients maintaining also their ability to suppress T-cell proliferation [27]. A recent paper [4] 
showed, however, a significant lower expression of FOXP3+ Treg cells in the lesional skin of BP compared 
with PV patients, coupled with an accumulation of Th17 cells. 
The aim of this study was to investigate the expression and phenotypes of two distinct Treg circulating 
subsets (CD4+ CD25brightFOXP3+ and CD8+ CD28-) in BP patients to clarify whether the depletion of this 
subset constitutes one potential mechanism of tolerance loss induction. 
 
 
Materials and methods 
Patients 
Twenty-six BP patients (17 males, 9 females; median age 74 years, range: 59–88) were enrolled, after 
getting their written informed consent, in two Italian dermatological centres (Florence and Turin). The 
study was approved by the Ethics Committee in each institution. All the patients were included at the time 
of first BP diagnosis before receiving steroids or other immuno-suppressive therapies. BP diagnosis was 
based on the following criteria: typical clinical features, with skin blistering in elderly patients; 
subepidermal blistering and eosinophil/neutrophil inflammatory infiltrate; linear IgG/C3 deposits along the 
dermal-epidermal junction at direct immunofluorescence examination, linear IgG deposits at the blister 
roof of sodium chloride split human skin at indirect immunofluorescence; circulating anti-BPAg2 (collagen 
XVII/BP180) antibodies at enzyme-linked immunosorbent assay (ELISA). Disease extent and severity was 
graded according to the ABSIS score (autoimmune bullous skin disorder intensity score) [24] (scoring range 
0–206, 150 points maximum for skin involvement, 11 for oral involvement and 45 for subjective 
discomfort).  
Flow cytometric analysis 
Peripheral blood sampling was performed during the first visit before systemic treatment was started. A 
group of age- and sex-matched healthy subjects (n = 30) were used as healthy controls (HC). Peripheral 
blood lymphocyte samples were evaluated according to their immunofluorescence  reactivity using 
FACSCalibur/FACSCanto TM II cytometers and analyzed with CellQuest/FACSDiva (Becton–Dickinson, San 
Jose`, CA, USA). Surface markers were performed by four- or six-colour immunofluorescence analyses, 
using simultaneously antibodies conjugated to FITC, PE, PerCP or PerCP Cy5.5, Pe-Cy7, APC and APC-H7. At 
least 10,000 lymphocytes were collected for each antibody combination. Lymphocyte purity was verified by 
standard forward and sideways scattering parameters, using a CD45 gating analysis. The following MoAbs 
were analysed: CD3 FITC, PerCP Cy5.5 or APC-H7 (SK7, mouse IgG1), CD4 PerCP or Pe-Cy7 (SK3, mouse 
IgG1) CD8 APC-H7 (SK1, mouse IgG1), CD16 FITC (NKP15, mouse IgG1), CD19 APC (SJ25C1, mouse IgG1), 
CD28 PE (CD28.2, IgG1), CD56 PE (MY31, IgG1), anti-CCR4 PE (IG1, IgG1), anti CD25 PE or APC (M-A251, 
mouse IgG1), anti CD62L PE or APC (Dreg 56, mouse IgG1), all purchased from BD Biosciences (San Diego, 
CA, USA).  
The CD4+ CD25+ population can be divided into two different levels of expression, i.e. low CD25 level 
(defined CD4+ CD25low) and high CD25 level (defined CD4+ CD25bright) [9–13] that appear to have a tail to 
the right of the major population containing both CD4+ CD25low and CD4+ CD25- cells. FOXP3 expression 
was analysed using mononuclear cells purified from peripheral blood using Lymphoprep (1.077 g mL; Axis-
Shield, Oslo, Norway) density gradient centrifugation. The cells were incubated with surface antibodies, 
anti-CD4 PerCP or PE-Cy7 and anti-CD25 APC for 10 min at room temperature, then stained with anti-
FOXP3 PE (clone PCH101, rat IgG2a; eBiosciences, San Diego, CA, USA), according to the manufacturer’s 
protocol, using fixation and permeabilisation buffers from the same provider. nTreg values were 
determined as the percentage of CD25brightFOXP3+ within the CD3+ CD4+ compartment. Statistical 
analysis The results are presented as medians, 25th- and 75th-percentile. The Mann–Whitney U test and 
the Kruskal–Wallis with Dunn posthoc test were used to compare data, giving similar results. p\0.05 was 
considered statistically significant. 
 
Results 
Circulating T-cell subsets  
No significant differences in the median percentage values of circulating T CD3+ CD4+ and CD3+ CD8+, B 
and natural killer (NK) cells were found between BP patients and HC (Table 1). By contrast, 
CD25brightFOXP3+ expression within the CD4+ subset was significantly lower in BP patients (median: 1.8%, 
25th–75th percentile: 1–3.1%) than in HC (median: 3.5%, 25th–75th percentile: 3–4%) (p = 0.002) (Fig. 1a). 
The same differences were demonstrated when considering absolute values of the circulating CD4 
+CD25brightFOXP3 + subset (median 20 cells/ll, 25th–75th percentile: 13–35, in BP versus 28 cells/ll, 21–31, 
in HC) (p = 0.05) (Fig. 1b).No relationship was found between levels of CD4+ CD25brightFOXP3+ and the 
disease extent as determined by the ABSIS score. No significant differences in the percentage expression of 
CD28- cells within the CD8+ T-cell population werefound between BP patients and HC. 
CD25 expression intensity and CCR4, CD62L and FOXP3 phenotype characterization 
On the basis of CD25 expression, three separate sub-populations have been singled out, CD4+ CD25bright, 
CD4+ CD25low and CD4+ CD25- cells. CD4+ CD25- absolute circulating cells were significantly higher in HC 
(median: 502 cells/ll, 25th–75th percentile: 428–545) than in BP (median 281 cells/ll, 25th–75th percentile: 
237–367) (p = 0.001). No differences between BP and HC could be found in absolute CD4 + CD25low cells 
(median BP: 370 cells/ll, 25th–75th percentile, vs. 412 cells/ll, 313–542 in HC). On the other hand, CD4+ 
CD25bright cells constituted a small subgroup, with a significantly higher percentage (median = 4.7 and 
2.8%, respectively) and absolute expression (median 244 cells/ll, 25th–75th percentile: 106–575 and 37 
cells/ll, 21–98) in BP than in HC (p = 0.001).  
CCR4+, CD62L+ and FOXP3+ expression were analysed within these three different T-cell subsets in both BP 
patients and HC (Table 2). CCR4 was expressed on CD4+ CD25bright cells in both BP and HC (median 71.2 
and 74.8%, respectively) and significantly decreased in CD4+ CD25low (47.9 and 34.6%, respectively) and, 
particularly, CD4+ CD25- cells (16 and 18%, respectively) (p = 0.0001 in BP and p = 0.0001 in HC; Kruskal–
Wallis test), without differences between BP patients and HC.  
CD62L was expressed on both CD4+ CD25bright and CD4+ CD25low cells without significant differences 
between BP and HC. A significant CD62L reduction was found in the CD4+ CD25- subset only in BP patients 
(64.9%) with respect to HC (85.2%; p = 0.003). FOXP3 expression, as expected, was mainly confined to the 
CD4+ CD25bright subset, with less than 5% of FOXP3+ cells being observed in both CD4+ CD25low and 
CD4+CD25- cells (p\0.001). FOXP3 expression within the CD4+ CD25bright subset was significantly reduced 
in BP with respect to HC (median: 35.7 vs. 57.9%; p = 0.008) (Fig. 2). This implies that BP patients are 
characterised by a significant expansion of the CD25brightFOXP3- ‘‘activated’’ T-cell subset with respect to 
HC. CCR4 and CD62L were expressed on the majority of CD4+ CD25bright- FOXP3+ cells (median: 75.2 and 
82.3%, respectively).  
 
Discussion  
Our study shows for the first time that BP patients are characterised by a significant reduction in the 
percentage and absolute values of circulating CD4+ CD25bright-FOXP3+ Tregs, associated with an opposite 
up-regulation of the CD4+ CD25bright ‘‘inflammatory’’ cell subset. On the other hand, we failed to 
demonstrate a significant modification in CD8+ CD28- Treg cells [22, 34]. However, this latter subset has 
been found reduced in immune-driven diseases such as type-1 juvenile diabetes mellitus and systemic 
lupus erythematosus affecting predominantly young people [22, 34]; the age of the patients can play a role 
in this phenomenon as it is known that the CD8+ CD28- subset increases with age [12, 30] and BP affects 
predominantly elderly people (74 years median age in this study). The CD25bright expression does not 
exclusively identifies this T-cell population as it can be found also on activated T cells and APC [10, 19], 
whilst FOXP3 is the most exclusive Treg marker as the inhibitory properties lies in the FOXP3+ subset [10, 
18, 20, 32, 33]. Indeed, BP patients were characterised by a significant expansion of the CD4+ CD25bright 
and reduction of the CD4+ CD25- subset with respect to HC, which was coupled by an opposite marked 
down-regulation of the FOXP3+ compartment (64.3% of the CD4+ CD25bright subset were FOXP3 
negative). From a biological point of view, these data suggest that in BP patients, the Treg reduction is 
associated with an expansion of the ‘‘activated’’ CD25brightFOXP3- inflammatory compartment. These 
findings can at least partially explain the discrepancies between our study and that of Rensing-Ehl et al. 
[27]. Inthat paper, circulating Tregs were analysed on the basis of the CD25bright expression; even if FOXP3 
expression was reported to be higher among the CD4+ CD25bright subset, no specific comparison data as 
to FOXP3 expression in BP and HC are shown. The paper by Rensing-Ehl et al. [27] 
 reports two other main findings which are not available in our study, the presence of significant amounts 
of FOXP3+ cells in the lesional BP skin and the absence of functional Treg impairment. Indeed, patients with 
rheumatoid arthritis demonstrated a significant Treg increase in synovial fluid suggesting that recruitment 
to inflammatory sites may be responsible for circulating Treg reduction [23]. This phenomenon has not 
been demonstrated in BP, as the recent data by Arakawa et al. [4] showed a significant reduction in FOXP3+ 
cells in BP lesional skin compared with pemphigus vulgaris. As to the effective functional properties of 
these cells, the phenotypic characterisation performed in our study can give some more insights. Our data 
showed that the large majority (70–80%) of CD4+ CD25+ bright cells expressed CCR4 and CD62L. CCR4 is a 
chemokine receptor involved in the recruitment of skin-specific lymphocytes [7]. Hirahara et al. [16] 
showed that virtually all circulating CD4+ CD25brightFOXP3+ Treg expressed high CCR4 levels, and that this 
subset showed marked suppressive properties. CCR4 expression may drive Treg cells to sites of antigen 
presentation (such as the skin in BP patients) supporting the down-regulation ofT-cell activation [17]. As to 
CD62L expression, CD4+ CD25bright nTregs positive for L-selectin display a significantly stronger suppressor 
activity than the negative ones [15, 29]. Taken together, the CD4+ CD25bright- FOXP3+ cells shown to be 
reduced in BP patients exhibited the Tregs characteristic phenotypic features. The Treg phenotypic 
modulation shown by our study in BP patients is similar to that reported in PV patients where a reduction in 
circulating Tregs and a preferential CCR4 and CD62L expression on the CD4+ CD25bright cells were 
reported [31].  
In conclusion, this study shows for the first time a significant down-regulation of circulating Tregs in BP 
patients. Future studies are mandatory to identify the effective role of this modification in the disease 
pathogenesis as well as its relationship with the clinical response. 
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Fig. 1 Expression percentage levels of the CD25brightFoxP+ subpopulation within the CD4+ cell subset (Fig. 
1a) and absolute values of the CD4+CD25brightFOXP3+ cells (Fig. 1b) in BP patients and healthy controls. 










Fig. 2 Representative dot plots from a BP patient (Fig. 2a) and a normal control (HC, Fig. 2b) showing the 












Table 1 Circulating lymphocyte subsets in BP and HC 
____________________________________________________________________________________ 
Parameters    PB group (%)     Healthy control group (%) 
    __________________________ __________________________ 
Median     25th–75th percentile  Median     25th–75th percentile 
____________________________________________________________________________________ 
CD3+     75   72–80    73   69–76 
CD3+CD4+    49   43–57    51   43–53 
CD3+CD8+    26   17–33    20.5   18–20.5 
NK (CD3-CD16+/CD56+)  12   6–14    14   11–16 
B cells (CD19+)    9   4–12.5    10.5   8.7–13 
CD4+CD25brightFOXP3+a  1.8*   0.9–3.2   3.5*   3–4 
CD8+CD28-b    74   62.5–90   65   48–76.5 
___________________________________________________________________________________ 
* p=0.002 
a expressed as a percentage of CD25brightFOXP3+ cells within the CD4+ circulating compartment 






Table 2 Phenotype characterisation of circulating subsets on the basis of CD25 expression intensity 
__________________________________________________________________________________________________________________________________ 
                  CD4+CD25bright              CD4+CD25low                  CD4+CD25- 
_______________________________________          ____________________________________          ________________________________________ 
                  CCR4                  CD62L        FOXP3            CCR4             CD62L             FOXP3               CCR4                CD62L        FOXP3 
__________________________________________________________________________________________________________________________________ 
Healthy      74.8 (61.8–83)     88.6 (84.9–94.4)     57.9 (52.4–63.4)     47.9 (37.2–52.7)    75.4 (71.5–3.7)    4.7 (3.4–5.6)          18.0 (12.8–22.6)     85.2 (80.2 –89.2)     2.5 (1.3–3.7) 
controls 
 
BP            71.2 (51.6–84)     81.7 (70.6–89)        35.7 (20.0–61.9)      34.6 (19.5 –39.3)   77.6 (59.7–83.9)   1.6 (0.7–5.0)         13.8 (6.7–17.1)       64.9 (43.0 –75.7)    1.4 (0.7–2.4) 
patients 
__________________________________________________________________________________________________________________________________ 
Values are expressed as percentage median (25th–75th percentile in brackets) 
 
 
 
 
 
 
 
 
 
 
 
